ISV-305
Phase 3Completed 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Active, Symptomatic Blepharitis
Conditions
Active, Symptomatic Blepharitis
Trial Timeline
Mar 30, 2018 → Feb 4, 2020
NCT ID
NCT01543490About ISV-305
ISV-305 is a phase 3 stage product being developed by Sun Pharmaceutical for Active, Symptomatic Blepharitis. The current trial status is completed. This product is registered under clinical trial identifier NCT01543490. Target conditions include Active, Symptomatic Blepharitis.
What happened to similar drugs?
8 of 20 similar drugs in Active, Symptomatic Blepharitis were approved
Approved (8) Terminated (1) Active (11)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01543490 | Phase 3 | Completed |
| NCT03192137 | Phase 3 | Completed |
| NCT03192150 | Phase 3 | Completed |
Competing Products
20 competing products in Active, Symptomatic Blepharitis